Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Change in Acquisitions & Divestments (2023 - 2025)

Historic Change in Acquisitions & Divestments for GeneDx Holdings (WGS) over the last 3 years, with Q3 2025 value amounting to $7.2 million.

  • GeneDx Holdings' Change in Acquisitions & Divestments fell 5534.34% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.1 million, marking a year-over-year increase of 9213.2%. This contributed to the annual value of $41.1 million for FY2024, which is 13112.86% up from last year.
  • GeneDx Holdings' Change in Acquisitions & Divestments amounted to $7.2 million in Q3 2025, which was down 5534.34% from $12.8 million recorded in Q2 2025.
  • GeneDx Holdings' 5-year Change in Acquisitions & Divestments high stood at $16.7 million for Q3 2023, and its period low was $1.1 million during Q4 2023.
  • For the 3-year period, GeneDx Holdings' Change in Acquisitions & Divestments averaged around $10.3 million, with its median value being $12.8 million (2025).
  • As far as peak fluctuations go, GeneDx Holdings' Change in Acquisitions & Divestments skyrocketed by 136409.09% in 2024, and later plummeted by 5534.34% in 2025.
  • GeneDx Holdings' Change in Acquisitions & Divestments (Quarter) stood at $1.1 million in 2023, then surged by 1364.09% to $16.1 million in 2024, then tumbled by 54.98% to $7.2 million in 2025.
  • Its last three reported values are $7.2 million in Q3 2025, $12.8 million for Q2 2025, and $13.9 million during Q1 2025.